High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute

Abstract Background Durable remissions are observed in a fraction of metastatic melanoma patients treated with high-dose interleukin-2 (HD IL-2). Early studies reported overall (OR) and complete response (CR) rates of 16% and 8% respectively. Toxicity limited use to specialized centers with standard...

Full description

Bibliographic Details
Main Authors: Diwakar Davar, Fei Ding, Melissa Saul, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood, Hussein A. Tawbi
Format: Article
Language:English
Published: BMJ Publishing Group 2017-09-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Melanoma
Metastatic
Interleukin-2
HD IL-2
Immunotherapy
CTLA-4
Online Access:http://link.springer.com/article/10.1186/s40425-017-0279-5

Internet

http://link.springer.com/article/10.1186/s40425-017-0279-5

Similar Items